A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Clinical trial NCT05839626 · TERMINATED
Trial details
- NCT number
- NCT05839626
- Sponsor
- Sanofi
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-15
- Primary completion
- 2025-05-26
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.